Selenoesters and Selenoanhydrides as Novel Agents Against Resistant Breast Cancer
Open Access
- 1 July 2019
- journal article
- research article
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 39 (7) , 3777-3783
Abstract
Background/Aim: Selenium-containing compounds are becoming new alternatives in experimental chemotherapy in order to overcome multidrug resistance in cancer. The main goal of this study was to determine whether combined treatment with new Se-compounds would increase the effect of conventional doxorubicin chemotherapy in breast cancer cell lines. Materials and Methods: Se-compounds were evaluated regarding their cytotoxic and apoptosis-inducing effect on MCF-7 and ATP-binding cassette subfamily B member 1 (ABCB1)-overexpressing KCR breast cancer cell lines. Moreover, the interaction of Se-compounds with doxorubicin was assessed using the MTT assay. Results: Selenoanhydride exerted a selective activity towards the doxorubicin-resistant KCR cell line overexpressing ABCB1. Among the selenoesters, only ketone-containing selenoesters exerted significant cytotoxic activity against MCF-7 and KCR cell lines and the Se-compounds acted synergistically with doxorubicin on the KCR cell line. Conclusion: The importance of the COSeCH2COCH3 and COSeCH2CO(CH3)3 moieties for the cytotoxic and adjuvant role of Se-compounds was highlighted.Keywords
This publication has 16 references indexed in Scilit:
- Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatmentFree Radical Biology and Medicine, 2018
- Phase I trial of selenium plus chemotherapy in gynecologic cancersGynecologic Oncology, 2018
- Anthracycline Chemotherapy and CardiotoxicityCardiovascular Drugs and Therapy, 2017
- Selenoesters and selenoanhydrides as novel multidrug resistance reversing agents: A confirmation study in a colon cancer MDR cell lineBioorganic & Medicinal Chemistry Letters, 2017
- Identification of selenocompounds with promising properties to reverse cancer multidrug resistanceBioorganic & Medicinal Chemistry Letters, 2016
- Synthesis and antiproliferative activity of novel selenoester derivativesEuropean Journal of Medicinal Chemistry, 2014
- Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A ReviewJournal of Drug Delivery, 2013
- Doxorubicin pathwaysPharmacogenetics and Genomics, 2011
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006